A report says AstraZeneca is cutting about 600 U.S. jobs from its respiratory and immunology commercial teams as part of a three-year cost-saving plan. The coverage links the roles at least in part to marketing for asthma drugs Breztri and Airsupra, with the company declining to comment. The restructuring implies near-term changes in commercial execution and staffing models across branded respiratory and immunology portfolios. It also reinforces a broader industry pattern of shifting resources between go-to-market and R&D priorities. For biotech and pharma partners, staff reductions can affect service levels, channel strategy, and the cadence of evidence-generation and payer engagement tied to marketed products.